For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
What Trump’s vaccine executive order actually does
Yesterday, President Trump signed an executive order directing federal health agencies to revise childhood vaccine recommendations, reducing the number of vaccines recommended for…
Blog
Trump administration decision highlights disastrous Part D redesign
The Trump administration recently announced the end of a demonstration project that was pulled together by the Biden administration as the Inflation Reduction…
Blog
Fauci’s lasting legacy will be the damage he did to science and government
Anthony Fauci isn’t faring well in the court of public opinion. His recently divulged “diary” and subsequent July 29 appearance before the Senate Homeland…
Search Posts
Citation
Think Tank: More FDA 510(k) Oversight Needed, Driving Innovation Overseas
Citation
Competitive Enterprise Institute Criticizes the FDA
Citation
Conservative think tank report blasts FDA
Citation
News Bites: Bachmann’s IPAB Claims Fall Flat
News Release
New Study Reveals Mismanagement of FDA Medical Device Reviews
Washington, D.C., October 12, 2011—The Food and Drug Administration’s 510(k) review process for medical devices has been severely mismanaged by agency officials, according to…
Study
Stifling Medical Device Innovation
The United States has long been the home to cutting-edge innovations in the medical device industry. However, increasingly burdensome regulatory policy is driving pioneering research…